Floatz logo

MANNITOL

Renal Cancer

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

298 Active assets in the Renal Cancer cohort.

Asset / SponsorPhaseRating
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB

View all 50 →

Same molecule, other indications

MANNITOL is also rated in:

cystic fibrosisDormant
BB
Indicative ·
69 / 100
View asset →
Intracranial HypertensionDormant
BB
Indicative ·
67 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →